open access

Vol 76, No 5 (2018)
Reviews
Published online: 2018-04-06
Submitted: 2018-04-04
Accepted: 2018-04-04
Get Citation

Reperfusion treatment in acute myocardial infarction in elderly patients

Frans Van de Werf
DOI: 10.5603/KP.a2018.0092
·
Kardiol Pol 2018;76(5):830-837.

open access

Vol 76, No 5 (2018)
Reviews
Published online: 2018-04-06
Submitted: 2018-04-04
Accepted: 2018-04-04

Abstract

In this paper the current knowledge of reperfusion therapy in elderly patients with an ST-segment elevation acute myocardial infarction (STEMI) is summarised. Placebo-controlled trials of fibrinolytic agents, direct comparative trials of fibrinolytic agents and antithrombotic co-therapies, and randomised trials of primary percutaneous coronary intervention (PCI) versus fibrinolytic therapy as well as registries are briefly reviewed, focusing on the impact of age. The benefit and risk of a combined pharma-cological and mechanical approach is presented. Important differences between a “facilitated PCI” and a “pharmaco-invasive strategy”, particularly in older STEMI patients, are highlighted. It will become clear at the end of this review that the knowledge about the benefit and risk of reperfusion therapy in the elderly is still incomplete and that more clinical trials in the elderly are needed. Practical recommendations for elderly patients with STEMI based on the current knowledge have been provided.

Abstract

In this paper the current knowledge of reperfusion therapy in elderly patients with an ST-segment elevation acute myocardial infarction (STEMI) is summarised. Placebo-controlled trials of fibrinolytic agents, direct comparative trials of fibrinolytic agents and antithrombotic co-therapies, and randomised trials of primary percutaneous coronary intervention (PCI) versus fibrinolytic therapy as well as registries are briefly reviewed, focusing on the impact of age. The benefit and risk of a combined pharma-cological and mechanical approach is presented. Important differences between a “facilitated PCI” and a “pharmaco-invasive strategy”, particularly in older STEMI patients, are highlighted. It will become clear at the end of this review that the knowledge about the benefit and risk of reperfusion therapy in the elderly is still incomplete and that more clinical trials in the elderly are needed. Practical recommendations for elderly patients with STEMI based on the current knowledge have been provided.

Get Citation

Keywords

ST-segment elevation myocardial infarction, fibrinolysis, primary percutaneous coronary intervention, elderly

About this article
Title

Reperfusion treatment in acute myocardial infarction in elderly patients

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 76, No 5 (2018)

Pages

830-837

Published online

2018-04-06

DOI

10.5603/KP.a2018.0092

Bibliographic record

Kardiol Pol 2018;76(5):830-837.

Keywords

ST-segment elevation myocardial infarction
fibrinolysis
primary percutaneous coronary intervention
elderly

Authors

Frans Van de Werf

References (21)
  1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994; 343(8893): 311–322.
  2. Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation. 2000; 101(19): 2239–2246.
  3. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old. Arch Intern Med. 2002; 162(5): 561–568.
  4. Berger AK, Radford MJ, Wang Y, et al. Thrombolytic therapy in older patients. J Am Coll Cardiol. 2000; 36(2): 366–374.
  5. Stenestrand U, Wallentin L. Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. Arch Intern Med. 2003; 163(8): 965–971.
  6. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003; 349(8): 733–742.
  7. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation. 1996; 94(8): 1826–1833.
  8. Wang-Clow F, Fox NL, Cannon CP, et al. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J. 2001; 141(1): 33–40.
  9. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Lancet. 1999; 354(9180): 716–722.
  10. Chen ZM, Jiang LX, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366(9497): 1607–1621.
  11. Sabatine MS, Cannon CP, Gibson CM, et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352(12): 1179–1189.
  12. Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013; 368(15): 1379–1387.
  13. Berwanger O, Nicolau JC, Carvalho AC, et al. Writing Committee for the TREAT Study Group. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2018 [Epub ahead of print].
  14. Antman EM, Morrow DA, McCabe CH, et al. ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006; 354(14): 1477–1488.
  15. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7; 39(2): 119–177.
  16. Grines C. SENIOR PAMI: a prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction. Presented at: Transcatheter Cardiovascular Therapeutics 2005; October 19, 2005; Washington, DC. 2005.
  17. Bueno H, Betriu A, Heras M, et al. TRIANA Investigators. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011; 32(1): 51–60.
  18. Mehta RH, Granger CB, Alexander KP, et al. Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. J Am Coll Cardiol. 2005; 45(4): 471–478.
  19. Vora AN, Holmes DN, Rokos I, et al. Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. JAMA Intern Med. 2015; 175(2): 207–215.
  20. Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J. 2012; 33(10): 1232–1240.
  21. Pu J, Ding S, Ge H, et al. EARLY-MYO Investigators. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation. 2017; 136(16): 1462–1473.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl